SOUTH SAN FRANCISCO (dpa-AFX) - Lixte Biotechnology Holdings, Inc. (LIXT),
Friday announced a partnership with Swiss healthcare company Roche Holding AG
(RHHBY) and the Netherlands Cancer Institute to conduct a new clinical trial for
immune therapy unresponsive metastatic colon cancer.

In the trial listed as NCT06012734, Lixte will contribute its lead compound
LB-100, which helps in enhancing response to immunotherapy, whereas Roche will
provide atezolizumab and financial support.

Currently, LIXTE's stock is moving up 8.6 percent, to $2.8 on the Nasdaq.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX